Novo Nordisk A/S $NVO is Foresight Global Investors Inc.'s 10th Largest Position

Key Points

• Foresight Global Investors cut its stake in Novo Nordisk by 31.7% in Q3, leaving it with 165,294 shares worth $9.17 million and making NVO its 10th largest holding (≈5.4% of the fund).
• Novo Nordisk reported a quarterly beat (EPS $1.01 vs. $0.90; revenue $12.43B) and trades around $39.02 with a market cap of $174.2B, but its 1‑year range shows significant volatility ($35.85–$89.03).
• Regulatory and legal risks are rising—multiple FDA warning letters over GLP‑1 ads, AHA pushback on a 340B policy and an investor probe—while analyst sentiment is mixed (average rating: Hold, consensus target $53.93) amid notable price‑target cuts and selective upgrades.

Foresight Global Investors Inc. cut its holdings in Novo Nordisk A/S (NYSE:NVO - Free Report) by 31.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 165,294 shares of the company's stock after selling 76,872 shares during the quarter. Novo Nordisk A/S makes up approximately 5.4% of Foresight Global Investors Inc.'s holdings, making the stock its 10th largest holding. Foresight Global Investors Inc.'s holdings in Novo Nordisk A/S were worth $9,172,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Martin Capital Partners LLC increased its position in shares of Novo Nordisk A/S by 53.8% during the third quarter. Martin Capital Partners LLC now owns 117,577 shares of the company's stock valued at $6,524,000 after buying an additional 41,129 shares during the period. Smith Chas P & Associates PA Cpas boosted its position in Novo Nordisk A/S by 105.3% during the 3rd quarter. Smith Chas P & Associates PA Cpas now owns 405,425 shares of the company's stock valued at $22,497,000 after acquiring an additional 207,959 shares in the last quarter. Clifford Swan Investment Counsel LLC grew its holdings in shares of Novo Nordisk A/S by 13.7% during the 3rd quarter. Clifford Swan Investment Counsel LLC now owns 311,168 shares of the company's stock worth $17,267,000 after acquiring an additional 37,453 shares during the period. Markel Group Inc. raised its position in shares of Novo Nordisk A/S by 4.9% in the 3rd quarter. Markel Group Inc. now owns 2,368,649 shares of the company's stock worth $131,436,000 after acquiring an additional 110,061 shares in the last quarter. Finally, Cantor Fitzgerald Investment Advisors L.P. purchased a new position in shares of Novo Nordisk A/S in the 3rd quarter valued at approximately $1,294,000. Institutional investors own 11.54% of the company's stock.

Analyst Ratings Changes

NVO has been the topic of several recent research reports. The Goldman Sachs Group reaffirmed a "neutral" rating and issued a $41.00 price target (down from $63.00) on shares of Novo Nordisk A/S in a research note on Monday. Argus reaffirmed a "hold" rating on shares of Novo Nordisk A/S in a research report on Monday, December 8th. Zacks Research cut shares of Novo Nordisk A/S from a "hold" rating to a "strong sell" rating in a research report on Monday, February 9th. JPMorgan Chase & Co. reissued a "neutral" rating on shares of Novo Nordisk A/S in a research note on Tuesday, February 24th. Finally, Morgan Stanley upgraded shares of Novo Nordisk A/S from an "underweight" rating to an "equal weight" rating and set a $40.00 price objective on the stock in a report on Tuesday. Five research analysts have rated the stock with a Buy rating, seventeen have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Novo Nordisk A/S currently has an average rating of "Hold" and a consensus target price of $53.93.

Novo Nordisk A/S Stock Performance

Shares of Novo Nordisk A/S stock opened at $39.02 on Friday. Novo Nordisk A/S has a 1 year low of $35.85 and a 1 year high of $89.03. The firm's 50-day moving average is $51.68 and its 200 day moving average is $52.48. The stock has a market cap of $174.22 billion, a price-to-earnings ratio of 11.24 and a beta of 0.73. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.80 and a quick ratio of 0.57.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.90 by $0.11. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. The business had revenue of $12.43 billion during the quarter, compared to analysts' expectations of $11.97 billion. Sell-side analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Dividend Announcement

The firm also recently announced a dividend, which will be paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th will be paid a dividend of $1.2751 per share. This represents a yield of 541.0%. The ex-dividend date is Monday, March 30th. Novo Nordisk A/S's dividend payout ratio (DPR) is currently 52.74%.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Morgan Stanley raised NVO to Equal Weight, reducing downside concerns from that shop and providing some support for the shares. Novo Nordisk A/S NYSE: NVO Raised to Equal Weight at Morgan Stanley
• Positive Sentiment: Market reaction to the FDA’s tighter scrutiny of telehealth GLP‑1 advertisers lifted NVO as investors expect larger incumbent manufacturers to benefit if smaller/telehealth competitors face limits. Novo Nordisk (NVO) Stock Jumps 3% as FDA Cracks Down on Telehealth GLP-1 Advertisers
• Neutral Sentiment: Goldman Sachs reiterated a Neutral rating on NVO, leaving the firm’s guidance unchanged and offering little directional push. The Goldman Sachs Group Reaffirms "Neutral" Rating for Novo Nordisk A/S NYSE: NVO
• Neutral Sentiment: Market commentary is debating Novo Nordisk’s valuation after the recent share decline; some pieces argue pessimism may be overdone while others call for catalyst clarity — this keeps near-term sentiment mixed. Novo Nordisk NYSE: NVO Valuation Debate Lingers As Market Awaits Catalyst Clarity
• Neutral Sentiment: Analysis pieces are questioning whether the recent selloff has priced in too much pessimism, which can attract value‑oriented buyers if fundamentals hold. Is Novo Nordisk NYSE: NVO Now Pricing In Too Much Pessimism After Share Price Slump
• Negative Sentiment: FDA has issued another warning letter to Novo Nordisk over an “Only One Ozempic” ad and broader GLP‑1 advertising concerns — increased regulatory scrutiny of marketing claims raises compliance risk and potential reputational damage. Novo Nordisk slammed with another FDA letter for ‘Only One Ozempic’ ad
• Negative Sentiment: Additional reporting confirms the FDA’s second warning over GLP‑1 ads, reinforcing regulatory/headline risk that could pressure sentiment and invite closer agency oversight. FDA sends Novo Nordisk 2nd warning over GLP-1 ads
• Negative Sentiment: The American Hospital Association urged HRSA to block Novo Nordisk’s new claims-data submission policy for 340B hospitals, signaling potential pushback from hospital customers and possible distribution/contracting friction. AHA urges HRSA to stop Novo Nordisk’s new claims-data submission policy on 340B hospitals from going into effect
• Negative Sentiment: Pomerantz LLP announced an investor investigation into Novo Nordisk, which could foreshadow litigation or shareholder claims and add legal uncertainty. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S - NVO

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.